Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16) [Reuters]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Reuters
Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16) | Reuters 2 Min Read (This version of the August 16th story corrects to change drug price in headline, first bullet, paragraphs 1 and 3 after company corrects it to $16,970 from $15,970) By Manas Mishra (Reuters) - Japan’s Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $17,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer. The drug was approved as the first therapy in over a decade in the United States to treat previously untreated patients with an advanced or intermediate stage of unresectable hepatocellular carcinoma (HCC). “The price at which the recommended starting dose of Lenvima for unresectable HCC will be sold to wholesalers, excluding discounts, is $16,970 for a 30-day supply,” Eisai told Reuters. The price will be “in parity” with the prices of available doses, Chief O
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck (MRK) Rises Higher Than Market: Key Facts [Yahoo! Finance]Yahoo! Finance
- [Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) [Yahoo! Finance]Latest
- WebMD Health Services Announces Employee Engagement Solution Returns to Its Iconic Brand Name, TINYpulse [Yahoo! Finance]Yahoo! Finance
- How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together [Yahoo! Finance]Yahoo! Finance
- Global Montelukast Sodium Market Report 2024: A USD 2.24 Billion Market by 2034 at a CAGR of 15.7%, Driven by Rising Prevalence of Respiratory Diseases and Enhanced Drug Formulations [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/1/24 - Beat
MRK
Sec Filings
- 3/28/24 - Form PX14A6G
- 3/19/24 - Form S-3ASR
- 3/19/24 - Form S-3ASR
- MRK's page on the SEC website